论文部分内容阅读
目的:比较紫杉醇微孔载药支架和进口雷帕霉素药物洗脱支架在经皮冠状动脉介入治疗中的临床疗效。方法:筛选73例行经皮冠状动脉介入治疗术的冠心病患者,随机分为两组,紫杉醇微孔载药支架组(紫杉醇组,35例)和进口雷帕霉素药物洗脱支架组(雷帕霉素组,38例)。支架植入术后6个月复查冠状动脉造影(CAG)。随访6个月,对比两组支架内血栓形成、主要心血管不良事件(包括心源性死亡、非致死性心肌梗死、靶病变血运重建)和支架内再狭窄发生率。结果:随访6个月,两组均未出现急性、亚急性和晚期支架内血栓形成、非致死性心肌梗死和心源性死亡。心绞痛、支架内再狭窄和靶病变血运重建发生率均无统计学差异。结论:紫杉醇微孔载药支架与进口雷帕霉素药物洗脱支架在治疗冠状动脉简单病变时具有相同的近、中期临床疗效和安全性。
OBJECTIVE: To compare the clinical efficacy of paclitaxel microporous drug-eluting stents and imported rapamycin-eluting stents in percutaneous coronary intervention. Methods: Seventy-three patients with coronary artery disease undergoing percutaneous coronary intervention were randomly divided into two groups: paclitaxel microporous stent group (paclitaxel group, 35 cases) and imported rapamycin eluting stent group Rapamycin group, 38 cases). Coronary angiography (CAG) was reviewed 6 months after stenting. The patients were followed up for 6 months. The incidence of stent thrombosis, major cardiovascular adverse events (including cardiac death, non-fatal myocardial infarction, target revascularization) and the incidence of in-stent restenosis were compared between the two groups. RESULTS: Acute, subacute, and late stent thrombosis, non-fatal myocardial infarction, and cardiac death did not occur in both groups at follow-up of 6 months. There was no significant difference in angina pectoris, in-stent restenosis and target revascularization. CONCLUSION: Paclitaxel microporous drug-eluting stent has the same clinical efficacy and safety as the imported rapamycin-eluting stent in the treatment of simple coronary lesions.